FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136117018> ?p ?o ?g. }

• W3136117018 endingPage "806" @default.
• W3136117018 startingPage "800" @default.
• W3136117018 abstract "What is known and Objective Hydroxychloroquine and protease inhibitors were widely used as off-label treatment options for COVID-19 but the safety data of these drugs among the COVID-19 population are largely lacking. Drug-induced QTc prolongation is a known adverse reaction of hydroxychloroquine, especially during chronic treatment. However, when administered concurrently with potential pro-arrhythmic drugs such as protease inhibitors, the risk of QTc prolongation imposed on these patients is not known. We aim to investigate the incidence of QTc prolongation events and potential factors associated with its occurrence in COVID-19 population. Methods We included 446 SARS-CoV-2 RT-PCR-positive patients taking at least one treatment drug for COVID-19 within a period of one month (March–April 2020). In addition to COVID-19-related treatment (HCQ/PI), concomitant drugs with risks of QTc prolongation were considered. We defined QTc prolongation as QTc interval of ≥470 ms in postpubertal males, and ≥480 ms in postpubertal females. Results and Discussion QTc prolongation events occurred in 28/446 (6.3%) patients with an incidence rate of 1 case per 100 person-days. A total of 26/28 (93%) patients who had prolonged QTc intervals received at least two pro-QT drugs. Multivariate analysis showed that HCQ and PI combination therapy had five times higher odds of QTc prolongation as compared to HCQ-only therapy after controlling for age, cardiovascular disease, SIRS and the use of concurrent QTc-prolonging agents besides HCQ and/or PI (OR 5.2; 95% CI, 1.11-24.49; p = 0.036). Independent of drug therapy, presence of SIRS resulted in four times higher odds of QTc prolongation (OR 4.3; 95% CI, 1.66-11.06; p = 0.003). In HCQ-PI combination group, having concomitant pro-QT drugs led to four times higher odds of QTc prolongation (OR 3.8; 95% CI, 1.53-9.73; p = 0.004). Four patients who had prolonged QTc intervals died but none were cardiac-related deaths. What is new and conclusion In our cohort, hydroxychloroquine monotherapy had low potential to increase QTc intervals. However, when given concurrently with protease inhibitors which have possible or conditional risk, the odds of QTc prolongation increased fivefold. Interestingly, independent of drug therapy, the presence of systemic inflammatory response syndrome (SIRS) resulted in four times higher odds of QTc prolongation, leading to the postulation that some QTc events seen in COVID-19 patients may be due to the disease itself. ECG monitoring should be continued for at least a week from the initiation of treatment." @default.
• W3136117018 created "2021-03-29" @default.
• W3136117018 creator A5001646775 @default.
• W3136117018 creator A5005370503 @default.
• W3136117018 creator A5033548637 @default.
• W3136117018 creator A5071244910 @default.
• W3136117018 creator A5079861875 @default.
• W3136117018 date "2021-03-25" @default.
• W3136117018 modified "2023-09-26" @default.
• W3136117018 title "QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID‐19" @default.
• W3136117018 cites W2022501241 @default.
• W3136117018 cites W2082072065 @default.
• W3136117018 cites W2095861052 @default.
• W3136117018 cites W2140996141 @default.
• W3136117018 cites W2161070289 @default.
• W3136117018 cites W2595229859 @default.
• W3136117018 cites W2767891136 @default.
• W3136117018 cites W2768146862 @default.
• W3136117018 cites W2790275782 @default.
• W3136117018 cites W3005212621 @default.
• W3136117018 cites W3008372187 @default.
• W3136117018 cites W3009144220 @default.
• W3136117018 cites W3009389929 @default.
• W3136117018 cites W3009577418 @default.
• W3136117018 cites W3012379316 @default.
• W3136117018 cites W3012421327 @default.
• W3136117018 cites W3015907249 @default.
• W3136117018 cites W3016514446 @default.
• W3136117018 cites W3021000736 @default.
• W3136117018 cites W3022358203 @default.
• W3136117018 cites W3022946426 @default.
• W3136117018 cites W3023250042 @default.
• W3136117018 cites W3029983809 @default.
• W3136117018 cites W3031307765 @default.
• W3136117018 cites W3032398075 @default.
• W3136117018 cites W3034881489 @default.
• W3136117018 cites W3038420196 @default.
• W3136117018 cites W4238490980 @default.
• W3136117018 doi "https://doi.org/10.1111/jcpt.13356" @default.
• W3136117018 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8250811" @default.
• W3136117018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33768612" @default.
• W3136117018 hasPublicationYear "2021" @default.
• W3136117018 type Work @default.
• W3136117018 sameAs 3136117018 @default.
• W3136117018 citedByCount "3" @default.
• W3136117018 countsByYear W31361170182021 @default.
• W3136117018 countsByYear W31361170182022 @default.
• W3136117018 crossrefType "journal-article" @default.
• W3136117018 hasAuthorship W3136117018A5001646775 @default.
• W3136117018 hasAuthorship W3136117018A5005370503 @default.
• W3136117018 hasAuthorship W3136117018A5033548637 @default.
• W3136117018 hasAuthorship W3136117018A5071244910 @default.
• W3136117018 hasAuthorship W3136117018A5079861875 @default.
• W3136117018 hasBestOaLocation W31361170181 @default.
• W3136117018 hasConcept C118441451 @default.
• W3136117018 hasConcept C126322002 @default.
• W3136117018 hasConcept C156957248 @default.
• W3136117018 hasConcept C164705383 @default.
• W3136117018 hasConcept C2777672339 @default.
• W3136117018 hasConcept C2779123688 @default.
• W3136117018 hasConcept C2779134260 @default.
• W3136117018 hasConcept C2779703243 @default.
• W3136117018 hasConcept C2780486423 @default.
• W3136117018 hasConcept C2908647359 @default.
• W3136117018 hasConcept C3008058167 @default.
• W3136117018 hasConcept C42219234 @default.
• W3136117018 hasConcept C524204448 @default.
• W3136117018 hasConcept C71924100 @default.
• W3136117018 hasConcept C98274493 @default.
• W3136117018 hasConcept C99454951 @default.
• W3136117018 hasConceptScore W3136117018C118441451 @default.
• W3136117018 hasConceptScore W3136117018C126322002 @default.
• W3136117018 hasConceptScore W3136117018C156957248 @default.
• W3136117018 hasConceptScore W3136117018C164705383 @default.
• W3136117018 hasConceptScore W3136117018C2777672339 @default.
• W3136117018 hasConceptScore W3136117018C2779123688 @default.
• W3136117018 hasConceptScore W3136117018C2779134260 @default.
• W3136117018 hasConceptScore W3136117018C2779703243 @default.
• W3136117018 hasConceptScore W3136117018C2780486423 @default.
• W3136117018 hasConceptScore W3136117018C2908647359 @default.
• W3136117018 hasConceptScore W3136117018C3008058167 @default.
• W3136117018 hasConceptScore W3136117018C42219234 @default.
• W3136117018 hasConceptScore W3136117018C524204448 @default.
• W3136117018 hasConceptScore W3136117018C71924100 @default.
• W3136117018 hasConceptScore W3136117018C98274493 @default.
• W3136117018 hasConceptScore W3136117018C99454951 @default.
• W3136117018 hasIssue "3" @default.
• W3136117018 hasLocation W31361170181 @default.
• W3136117018 hasLocation W31361170182 @default.
• W3136117018 hasOpenAccess W3136117018 @default.
• W3136117018 hasPrimaryLocation W31361170181 @default.
• W3136117018 hasRelatedWork W3022946426 @default.
• W3136117018 hasRelatedWork W3082525515 @default.
• W3136117018 hasRelatedWork W3082969932 @default.
• W3136117018 hasRelatedWork W3091089782 @default.
• W3136117018 hasRelatedWork W3131959791 @default.
• W3136117018 hasRelatedWork W3136117018 @default.
• W3136117018 hasRelatedWork W4205357294 @default.

• next